Change of accounting reference date

RNS Number : 5134N
Avacta Group PLC
18 January 2019
 

 

 18 January 2019

 

Avacta Group plc

 

("Avacta", the "Group" or the "Company")

Change of accounting reference date

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents announces that it has changed its accounting reference date from 31 July to 31 December with immediate effect.

As a result of the change of accounting reference date, the Company's reporting calendar will be as follows:

 

·     Unaudited interim accounts for the 6 month period ended 31 January 2019 to be published by 30 April 2019;

 

·     publication of unaudited accounts for the 12 month period ended 31 July 2019 to be published by 31 October 2019; and

 

·     publication of audited final accounts for the 17 month period ended 31 December 2019 to be published by 31 May 2020.

 

Thereafter, interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies.

 

- Ends -

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern - ECM

 

WG Partners

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments

James Pope

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

 

Yellow Jersey (Financial Media and IR)

Sarah Hollins

Harriet Jackson

Tel: 020 3621 4120

james@turnerpope.com

 

Tel: +44 (0)7787 502 947

katie.odgaard@zymecommunications.com 

 

 

Tel: +44 (0)7764 947137

Tel: +44 (0)7544 275882

avacta@yellowjerseypr.com

 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUWVKRKNAAARR
UK 100

Latest directors dealings